Famed boot manufacturer Dr. Martens is anticipating a significant financial impact from US tariffs this year. The company, known for its iconic yellow-stitched boots, has disclosed that it is expecting a multimillion-pound blow due to increased import duties in Vietnam, where most of its footwear is now produced. This shift in production location was necessitated by the trade tensions instigated by US President Donald Trump’s policies.
Dr. Martens has taken proactive measures to mitigate the impact of tariffs, including diversifying its supply chain away from China, which previously contributed 50% of its production. Despite the tariff challenges, the company remains optimistic about meeting its full-year profit forecasts ranging between £53 million to £60 million, excluding the tariff-related losses.
The news of the expected tariff impact has affected Dr. Martens’ stock performance, with shares plunging over 10% in early trading. However, the company has outlined plans to counterbalance the tariff costs in the upcoming years through stringent cost controls, strategic sourcing, and adjustments to its pricing strategies in the USA.
In its latest financial update, Dr. Martens reported improved performance, narrowing its losses to £11 million in the first half of the year compared to £12.3 million in the previous year. Sales for the same period rose by 0.8% to £327.3 million, indicating positive momentum for the brand.
CEO Ije Nwokorie expressed confidence in the brand’s resilience, citing a significant increase in shoe volumes and successful launches of new products. Despite ongoing market uncertainties and consumer caution, Dr. Martens remains steadfast in its plans for the year ahead.
Investment director Russ Mould acknowledged the company’s efforts to revitalize its business, noting some positive indicators in the half-year results, such as reduced losses and improved performance in the Americas market. However, there remains a cautious sentiment among investors, as reflected in the initial market reaction with a decline in share prices.